USA: +1 617 939 9497 | UK: +44 2039 962936 | EU: +34 607 939 266 info@sofpromed.com
Select Page

CRO for Investigator-Initiated Clinical Trials (IIT)

Patricio Ledesma

Sofpromed's CEO and Founder. Global Director of Clinical Operations. 15+ years of experience in managing clinical trials.

18 November, 2026

Clinical researchers collaborating, with a diagram linking investigator-initiated trials and CRO support.

By Patricio Ledesma, Founder and CEO, Sofpromed

Table of Contents

Investigator-Initiated Trials (IITs) play a unique and indispensable role in clinical research.

While pharmaceutical companies sponsor the majority of industry-driven studies, many of the most important scientific questions are answered through investigator-led research conducted by academic institutions, hospitals, cooperative groups, and principal investigators.

Throughout my career in clinical research, I have worked with many academic investigators and research institutions facing the challenge of conducting high-quality clinical trials with limited resources.

Unlike large pharmaceutical companies, academic investigators often operate with small budgets, limited staff, and complex operational constraints.

Yet they are expected to meet exactly the same regulatory and scientific standards.

This is where experienced CRO support becomes critical.

At Sofpromed, we have extensive experience supporting Investigator-Initiated Trials across multiple therapeutic areas, particularly oncology.

Our teams understand the unique realities of IITs, including budget limitations, grant-funded research, academic governance structures, and the need for flexible, cost-effective clinical trial support.

In this article, I will discuss the growing importance of Investigator-Initiated Trials, the challenges faced by academic sponsors, best practices for successful oncology IITs, and how Sofpromed helps investigators bring innovative research ideas to life.

What Is an Investigator-Initiated Trial?

An Investigator-Initiated Trial is a clinical study in which the sponsor is an investigator, academic institution, hospital, university, or research consortium rather than a pharmaceutical or biotechnology company.

In an IIT, the Principal Investigator typically assumes sponsor responsibilities that may include:

  • Protocol development
  • Regulatory submissions
  • Safety oversight
  • Data management
  • Monitoring oversight
  • Statistical analysis
  • Final publication

The investigator is responsible for ensuring compliance with:

  • ICH E6(R3) Good Clinical Practice
  • FDA regulations
  • EU Clinical Trial Regulation (CTR)
  • Local ethics committee requirements
  • Data protection regulations

While many IITs receive financial support, study medication, or grants from pharmaceutical companies, the scientific control usually remains with the investigator.

Why Investigator-Initiated Trials Are Important

Many important medical advances originate from investigator-driven research.

Unlike industry-sponsored studies, IITs are often designed to answer questions that may have limited commercial value but substantial clinical importance.

Examples include:

  • Comparative effectiveness studies
  • Optimization of treatment schedules
  • Biomarker validation programs
  • Rare disease research
  • Academic oncology collaborations
  • Real-world evidence studies
  • Combination therapy investigations
  • Supportive care interventions

These studies frequently influence treatment guidelines and clinical practice worldwide.

Table 1. Key Differences Between Industry Trials and IITs

Characteristic

Industry Trial

Investigator-Initiated Trial

Sponsor

Pharmaceutical company

Investigator or academic institution

Primary objective

Regulatory approval

Scientific or clinical question

Funding source

Corporate budget

Grants, foundations, institutions

Resources

Extensive

Often limited

Operational support

Internal departments

Often outsourced

Publication rights

Sponsor-controlled

Investigator-led

Study flexibility

Moderate

Often higher

IITs often address clinically meaningful questions that would otherwise remain unanswered.

The Global Importance of Investigator-Initiated Research

Academic research continues to drive innovation globally.

Leading oncology breakthroughs have frequently emerged from investigator-led studies conducted by organizations such as:

  • Memorial Sloan Kettering Cancer Center
  • MD Anderson Cancer Center
  • Dana-Farber Cancer Institute
  • Mayo Clinic
  • European Organisation for Research and Treatment of Cancer (EORTC)
  • National Cancer Institute (NCI)

These institutions routinely conduct IITs that shape future standards of care.

Table 2. Typical Contributions of IITs to Clinical Research

Area

Contribution

Oncology

New treatment strategies

Rare Diseases

Generation of critical evidence

Biomarkers

Validation studies

Precision Medicine

Patient selection approaches

Academic Innovation

Early proof-of-concept research

Combination Therapies

Exploratory clinical evaluation

Real-World Evidence

Practical treatment insights

Many therapies currently considered standard of care were supported by academic studies long before industry sponsors pursued larger registration programs.

Why Oncology IITs Are Especially Important

Oncology represents one of the strongest areas of investigator-led research.

Cancer investigators continually seek answers to questions such as:

  • How can existing therapies be optimized?
  • Which biomarkers predict response?
  • Can approved drugs be used in new indications?
  • What combinations may improve outcomes?
  • Can toxicity be reduced?

These questions often emerge first in academic settings.

Table 3. Common Oncology IIT Objectives

Objective

Example

Biomarker research

ctDNA monitoring

Treatment sequencing

Optimal line selection

Dose optimization

Reduced toxicity regimens

Combination therapies

Immunotherapy combinations

Rare cancers

Small population studies

Translational research

Molecular profiling studies

Real-world validation

Standard of care evaluation

Academic oncology investigators frequently lead innovations that later become industry-sponsored programs.

Key Challenges Faced by IIT Sponsors

Although IITs are scientifically valuable, they face significant operational challenges.

Limited Budgets

The most common challenge is funding.

Unlike pharmaceutical companies, academic investigators frequently rely on:

  • Government grants
  • Cancer foundations
  • Public funding agencies
  • Institutional resources
  • Charitable organizations

Budgets are often a fraction of those available to industry-sponsored trials.

Table 4. Typical IIT Operational Constraints

Challenge

Impact

Limited funding

Reduced staffing

Small operations teams

Increased workload

Limited monitoring resources

Compliance risks

Complex contracts

Delayed startup

Academic timelines

Slower decision-making

Limited data management support

Database risks

Statistical resource limitations

Analysis delays

These constraints can significantly affect study success if not properly managed.

Regulatory Requirements Are the Same

One of the greatest misconceptions regarding investigator-led studies is that they face fewer regulatory requirements.

In reality, regulators expect the same level of compliance.

Investigators must ensure:

  • Good Clinical Practice compliance
  • TMF maintenance
  • Safety reporting
  • Monitoring oversight
  • Protocol adherence
  • Data integrity
  • Quality management

Whether the study budget is €200,000 or €20 million, compliance expectations remain essentially identical.

This makes experienced CRO support particularly valuable.

Why Academic Investigators Need CRO Support

Most investigators are experts in medicine and science.

Very few are experts in:

  • Trial management
  • Monitoring
  • Regulatory affairs
  • Data management
  • Statistics
  • Quality assurance

Attempting to build these capabilities internally can be extremely expensive.

Instead, many institutions partner with specialized CROs.

An experienced CRO can provide:

  • Infrastructure
  • Expertise
  • Technology
  • Regulatory knowledge

without requiring permanent institutional investment.

How Sofpromed Supports Investigator-Initiated Trials

At Sofpromed, we understand that IITs require a very different operational model than large pharmaceutical studies.

Academic sponsors need:

  • Flexibility
  • Scientific collaboration
  • Cost-effective solutions
  • Senior expertise
  • Efficient execution

Our approach is specifically designed to meet these needs.

Study Design and Protocol Development

The success of an IIT often begins with protocol design.

Our teams support investigators with:

  • Endpoint selection
  • Feasibility assessment
  • Sample size assumptions
  • Statistical methodology
  • Study operational planning

This early support helps prevent costly amendments later.

Clinical Data Management

Many IITs underestimate the complexity of data management.

A properly designed database can significantly improve study quality.

Sofpromed supports:

  • EDC setup
  • eCRF design
  • Edit checks
  • Data review plans
  • Data cleaning
  • Database lock preparation

For academic studies, efficient database design can save both time and budget.

Biostatistics and Statistical Programming

This is one area where academic sponsors often need substantial support.

Our biostatistics teams assist with:

  • Statistical Analysis Plans (SAPs)
  • Sample size calculations
  • Randomization design
  • Interim analyses
  • Final study reporting

We also provide:

  • SDTM datasets
  • ADaM datasets
  • TLF generation
  • Regulatory-compliant outputs

These services ensure high-quality scientific results while maintaining budget efficiency.

Clinical Monitoring Support

Monitoring remains essential for data quality and patient safety.

Sofpromed can support:

  • Site initiation visits
  • Routine monitoring visits
  • Remote monitoring
  • Source data verification
  • Site closeout activities

We tailor monitoring intensity according to study risk and available funding.

This is especially important in IIT environments where resources are limited.

Medical Writing Support

Academic investigators frequently need assistance preparing:

  • Study protocols
  • Investigator brochures
  • Clinical Study Reports
  • Conference abstracts
  • Manuscripts

Our medical writing teams help ensure scientific clarity and regulatory compliance.

Best Practices for a Successful Oncology IIT

After supporting multiple oncology studies throughout my career, I have observed several best practices that consistently improve outcomes.

1. Start with a Clinically Relevant Question

The strongest IITs address questions that matter directly to patient care.

Examples include:

  • Biomarker-guided treatment decisions
  • Treatment sequencing
  • Combination optimization
  • Rare tumor management

Scientific relevance drives recruitment and publication success.

2. Keep Study Design Realistic

Overly ambitious IITs frequently struggle.

Instead of pursuing dozens of exploratory endpoints, focus on:

  • One primary endpoint
  • Limited secondary endpoints
  • Clear analysis objectives

A focused study is often more successful than an overly complex one.

3. Build Statistical Expertise Early

Statistical planning should begin before protocol finalization.

Common mistakes include:

  • Underpowered studies
  • Inappropriate endpoints
  • Unrealistic assumptions

Early biostatistical involvement helps avoid these risks.

4. Select Investigators Carefully

Recruitment performance often determines study success.

High-performing oncology sites generally have:

  • Experienced research coordinators
  • Dedicated investigators
  • Strong patient populations
  • Established trial infrastructure

Site selection is one of the most important decisions in any IIT.

5. Prioritize Data Quality

Publications, conference presentations, and future funding depend on reliable data.

Best practices include:

  • Early edit checks
  • Risk-based monitoring
  • Timely query resolution
  • Consistent data review

High-quality data ultimately saves time and money.

6. Develop a Publication Strategy

Publication planning should begin before enrollment.

Consider:

  • Target journals
  • Conference presentations
  • Authorship strategy
  • Data cut timelines

Successful IITs are not measured only by completion but also by dissemination of results.

Why Sofpromed Is Well Positioned to Support IITs

Our experience has shown that academic studies require a unique mindset.

Large CRO models designed for multinational pharmaceutical studies are not always suitable for grant-funded research.

At Sofpromed, we have built our approach around:

Scientific Collaboration

We work closely with investigators and academic institutions as partners rather than vendors.

Cost Efficiency

We understand budget constraints.

Our lean operational model helps maximize available funding.

Flexible Resource Allocation

Investigators can access only the services they need.

Examples include:

  • Statistics only
  • Data management only
  • Monitoring only
  • Full-service support

Senior Expertise

Many IITs cannot afford multiple management layers.

Our model provides direct access to experienced professionals.

Supporting Global Academic Research

Modern IITs increasingly involve multiple countries.

Academic institutions may conduct studies across:

  • Europe
  • North America
  • Asia-Pacific
  • Latin America

Sofpromed can support multinational academic programs through:

  • Regulatory coordination
  • Data management
  • Monitoring
  • Biostatistics
  • Project management

This allows investigators to expand research beyond single-center studies and generate broader evidence.

The Future of Investigator-Initiated Trials

I believe the importance of IITs will continue to grow during the coming decade.

Several trends support this view:

Table 5. Future Drivers of IIT Growth

Trend

Expected Impact

Precision Oncology

Very High

Biomarker Development

Very High

Rare Cancer Research

High

Academic Collaborations

High

Real-World Evidence

High

Artificial Intelligence

Growing

Translational Medicine

Very High

Many of tomorrow's innovations will originate from academic investigators asking scientific questions that extend beyond traditional commercial objectives.

IITs will continue to play a critical role in generating these answers.

Conclusion

Investigator-Initiated Trials remain one of the most important engines of innovation in clinical research.

They allow academic investigators, hospitals, and research institutions to answer critical scientific questions that may not be addressed through traditional pharmaceutical development programs.

However, conducting successful IITs requires overcoming significant challenges, including limited funding, complex regulations, operational constraints, and increasing expectations regarding data quality and compliance.

Having spent many years working in clinical research, I have seen firsthand how the right operational support can transform an ambitious research idea into a successful study capable of influencing clinical practice and improving patient outcomes.

At Sofpromed, we are proud to support Investigator-Initiated Trials with flexible, cost-effective services tailored to the realities of academic research.

Our experience in oncology, data management, biostatistics, statistical programming, monitoring, medical writing, and project management allows us to help investigators conduct high-quality studies without the overhead often associated with large commercial CRO structures.

Whether supporting a single-center oncology trial, a multi-country academic collaboration, or a complex biomarker-driven precision medicine study, our objective remains the same: helping investigators generate robust scientific evidence efficiently, compliantly, and within budget.

As IITs continue to drive innovation across oncology and many other therapeutic areas, we look forward to partnering with academic investigators and institutions worldwide to bring the next generation of medical discoveries to patients.

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266  pledesma@sofpromed.com 

You may also be interested...

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266 pledesma@sofpromed.com